Reuters logo
BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE
September 5, 2017 / 2:42 PM / 16 days ago

BRIEF-EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

Sept 5 (Reuters) - Eagle Pharmaceuticals Inc

* EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE

* SAYS ‍ANALYSIS OF NEUROPATHOLOGY​ SHOWED LOWER LEVEL OF BRAIN CELL NECROSIS IN ANIMALS TREATED WITH RYANODEX + AEDS, COMPARED TO AEDS ALONE

* SAYS ‍IN ADDITION, NO SAFETY ISSUES WERE OBSERVED IN ANIMALS TREATED WITH RYANODEX​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below